Divarasib outperforms approved KRAS G12C inhibitors in NSCLC
esmo -
AI Summary: Divarasib delivered superior responses to existing KRAS G12C inhibitors in a head‑to‑head trial for KRAS G12C‑mutant non‑small‑cell lung cancer, producing higher tumor response and longer disease control while maintaining a manageable safety profile. The data position divarasib as a serious contender to displace older G12C agents if the effect holds up.
Related Stories
FDA speeds approval for dostarlimab in MSI‑H rectal cancer / 36 hrs
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 5 months
CA017‑078 results prompt reevaluation of perioperative nivolumab in MIBC / 24 hrs
Individualized mRNA neoantigen vaccine shows phase III success in melanoma / 27 hrs
Trastuzumab rezetecan (HORIZON‑Breast06) slashes progression risk by 73% / 37 hrs
Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 2 months
ENZAMET trial confirms long-term survival benefit of enzalutamide in mHSPC / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Hospital Operations, Clinical Trials, FDA, Cancer Screening and look for the RSS link.
StackHealth Time Machine